Duration of Tamoxifen Effect on Lipidemic Profile of Postmenopausal Breast Cancer Patients following Deprivation of Treatment
Objective: It was the aim of this study to investigate the effect of tamoxifen withdrawal on markers of lipid metabolism in postmenopausal women with breast cancer who completed tamoxifen therapy and received no further treatment. Methods: Lipidemic profile changes were studied in 190 postmenopausal...
Gespeichert in:
| Veröffentlicht in: | Oncology 2006-01, Vol.70 (4), p.301-305 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 305 |
|---|---|
| container_issue | 4 |
| container_start_page | 301 |
| container_title | Oncology |
| container_volume | 70 |
| creator | Markopoulos, C. Chrissochou, M. Antonopoulou, Z. Xepapadakis, G. Papadiamantis, J. Tzoracoleftherakis, E. Gogas, H. |
| description | Objective: It was the aim of this study to investigate the effect of tamoxifen withdrawal on markers of lipid metabolism in postmenopausal women with breast cancer who completed tamoxifen therapy and received no further treatment. Methods: Lipidemic profile changes were studied in 190 postmenopausal patients with operable breast cancer, following cessation of 5–7 years of tamoxifen treatment. Assessments of total cholesterol, high-density lipoprotein, low-density lipoprotein and total serum triglycerides were performed at baseline, 6 months and 12 months. Results: By 6 months, both total cholesterol and low-density lipoprotein levels were significantly increased, and total triglyceride levels were significantly reduced compared with baseline values and maintained to 12 months. There was no significant alteration observed for high-density lipoprotein levels over the study period. Conclusion: The beneficial effect of tamoxifen on the lipidemic profile of postmenopausal breast cancer patients seems to be lost in less than 12 months time following cessation of 5–7 years of tamoxifen treatment. A ‘rebound effect’ on the lipidemic parameters should be expected and those patients should be monitored carefully. |
| doi_str_mv | 10.1159/000096251 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_69027376</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69027376</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-4f43c781cea26f9493bbcd4842e9935708029a5fd882b6868b06ae6336aaf55f3</originalsourceid><addsrcrecordid>eNpd0c9rFDEUB_Agit1WD54FCYKCh9H8nsyxbqstLHQP9Ty8yb6U1JnJmsz449D_vVl26YK5BMIn773kS8gbzj5zrpsvrKzGCM2fkQVXQlZMSPGcLBiTrBKKqxNymvN9UbVW5iU54TVTtWJ8QR4u5gRTiCONnt7CEP8GjyO99B7dRMvxKmzDBofg6DpFH3rcwXXM04Bj3MKcoadfE0Ke6BJGh4muSz0cp0x97Pv4J4x39AK3Kfw-9il-d396RV546DO-Puxn5Me3y9vlVbW6-X69PF9VTho2Vcor6WrLHYIwvlGN7Dq3UVYJbBqpa2aZaED7jbWiM9bYjhlAI6UB8Fp7eUY-7utuU_w1Y57aIWSHfQ8jxjm3pmGilrUp8P1_8D7OaSyztUIwqzQXqqBPe-RSzDmhb8vrBkj_Ws7aXSDtUyDFvjsUnLsBN0d5SKCADwcA2UHvU_nEkI_OCqWl2U32du9-QrrD9AT2bR4BnYibaw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220845124</pqid></control><display><type>article</type><title>Duration of Tamoxifen Effect on Lipidemic Profile of Postmenopausal Breast Cancer Patients following Deprivation of Treatment</title><source>Karger Journals</source><source>MEDLINE</source><creator>Markopoulos, C. ; Chrissochou, M. ; Antonopoulou, Z. ; Xepapadakis, G. ; Papadiamantis, J. ; Tzoracoleftherakis, E. ; Gogas, H.</creator><creatorcontrib>Markopoulos, C. ; Chrissochou, M. ; Antonopoulou, Z. ; Xepapadakis, G. ; Papadiamantis, J. ; Tzoracoleftherakis, E. ; Gogas, H.</creatorcontrib><description>Objective: It was the aim of this study to investigate the effect of tamoxifen withdrawal on markers of lipid metabolism in postmenopausal women with breast cancer who completed tamoxifen therapy and received no further treatment. Methods: Lipidemic profile changes were studied in 190 postmenopausal patients with operable breast cancer, following cessation of 5–7 years of tamoxifen treatment. Assessments of total cholesterol, high-density lipoprotein, low-density lipoprotein and total serum triglycerides were performed at baseline, 6 months and 12 months. Results: By 6 months, both total cholesterol and low-density lipoprotein levels were significantly increased, and total triglyceride levels were significantly reduced compared with baseline values and maintained to 12 months. There was no significant alteration observed for high-density lipoprotein levels over the study period. Conclusion: The beneficial effect of tamoxifen on the lipidemic profile of postmenopausal breast cancer patients seems to be lost in less than 12 months time following cessation of 5–7 years of tamoxifen treatment. A ‘rebound effect’ on the lipidemic parameters should be expected and those patients should be monitored carefully.</description><identifier>ISSN: 0030-2414</identifier><identifier>EISSN: 1423-0232</identifier><identifier>DOI: 10.1159/000096251</identifier><identifier>PMID: 17047401</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Hormonal - administration & dosage ; Biological and medical sciences ; Breast cancer ; Breast Neoplasms - blood ; Breast Neoplasms - drug therapy ; Chemotherapy ; Cholesterol ; Clinical Study ; Drug Administration Schedule ; Female ; Gynecology. Andrology. Obstetrics ; Humans ; Lipid Metabolism - drug effects ; Lipids ; Lipids - blood ; Mammary gland diseases ; Medical sciences ; Metabolism ; Middle Aged ; Oncology ; Postmenopause ; Tamoxifen - administration & dosage ; Tumors</subject><ispartof>Oncology, 2006-01, Vol.70 (4), p.301-305</ispartof><rights>2006 S. Karger AG, Basel</rights><rights>2006 INIST-CNRS</rights><rights>Copyright (c) 2006 S. Karger AG, Basel.</rights><rights>Copyright (c) 2006 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-4f43c781cea26f9493bbcd4842e9935708029a5fd882b6868b06ae6336aaf55f3</citedby><cites>FETCH-LOGICAL-c360t-4f43c781cea26f9493bbcd4842e9935708029a5fd882b6868b06ae6336aaf55f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2423,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18245366$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17047401$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Markopoulos, C.</creatorcontrib><creatorcontrib>Chrissochou, M.</creatorcontrib><creatorcontrib>Antonopoulou, Z.</creatorcontrib><creatorcontrib>Xepapadakis, G.</creatorcontrib><creatorcontrib>Papadiamantis, J.</creatorcontrib><creatorcontrib>Tzoracoleftherakis, E.</creatorcontrib><creatorcontrib>Gogas, H.</creatorcontrib><title>Duration of Tamoxifen Effect on Lipidemic Profile of Postmenopausal Breast Cancer Patients following Deprivation of Treatment</title><title>Oncology</title><addtitle>Oncology</addtitle><description>Objective: It was the aim of this study to investigate the effect of tamoxifen withdrawal on markers of lipid metabolism in postmenopausal women with breast cancer who completed tamoxifen therapy and received no further treatment. Methods: Lipidemic profile changes were studied in 190 postmenopausal patients with operable breast cancer, following cessation of 5–7 years of tamoxifen treatment. Assessments of total cholesterol, high-density lipoprotein, low-density lipoprotein and total serum triglycerides were performed at baseline, 6 months and 12 months. Results: By 6 months, both total cholesterol and low-density lipoprotein levels were significantly increased, and total triglyceride levels were significantly reduced compared with baseline values and maintained to 12 months. There was no significant alteration observed for high-density lipoprotein levels over the study period. Conclusion: The beneficial effect of tamoxifen on the lipidemic profile of postmenopausal breast cancer patients seems to be lost in less than 12 months time following cessation of 5–7 years of tamoxifen treatment. A ‘rebound effect’ on the lipidemic parameters should be expected and those patients should be monitored carefully.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents, Hormonal - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Chemotherapy</subject><subject>Cholesterol</subject><subject>Clinical Study</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Lipid Metabolism - drug effects</subject><subject>Lipids</subject><subject>Lipids - blood</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Metabolism</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Postmenopause</subject><subject>Tamoxifen - administration & dosage</subject><subject>Tumors</subject><issn>0030-2414</issn><issn>1423-0232</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpd0c9rFDEUB_Agit1WD54FCYKCh9H8nsyxbqstLHQP9Ty8yb6U1JnJmsz449D_vVl26YK5BMIn773kS8gbzj5zrpsvrKzGCM2fkQVXQlZMSPGcLBiTrBKKqxNymvN9UbVW5iU54TVTtWJ8QR4u5gRTiCONnt7CEP8GjyO99B7dRMvxKmzDBofg6DpFH3rcwXXM04Bj3MKcoadfE0Ke6BJGh4muSz0cp0x97Pv4J4x39AK3Kfw-9il-d396RV546DO-Puxn5Me3y9vlVbW6-X69PF9VTho2Vcor6WrLHYIwvlGN7Dq3UVYJbBqpa2aZaED7jbWiM9bYjhlAI6UB8Fp7eUY-7utuU_w1Y57aIWSHfQ8jxjm3pmGilrUp8P1_8D7OaSyztUIwqzQXqqBPe-RSzDmhb8vrBkj_Ws7aXSDtUyDFvjsUnLsBN0d5SKCADwcA2UHvU_nEkI_OCqWl2U32du9-QrrD9AT2bR4BnYibaw</recordid><startdate>20060101</startdate><enddate>20060101</enddate><creator>Markopoulos, C.</creator><creator>Chrissochou, M.</creator><creator>Antonopoulou, Z.</creator><creator>Xepapadakis, G.</creator><creator>Papadiamantis, J.</creator><creator>Tzoracoleftherakis, E.</creator><creator>Gogas, H.</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20060101</creationdate><title>Duration of Tamoxifen Effect on Lipidemic Profile of Postmenopausal Breast Cancer Patients following Deprivation of Treatment</title><author>Markopoulos, C. ; Chrissochou, M. ; Antonopoulou, Z. ; Xepapadakis, G. ; Papadiamantis, J. ; Tzoracoleftherakis, E. ; Gogas, H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-4f43c781cea26f9493bbcd4842e9935708029a5fd882b6868b06ae6336aaf55f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents, Hormonal - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Chemotherapy</topic><topic>Cholesterol</topic><topic>Clinical Study</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Lipid Metabolism - drug effects</topic><topic>Lipids</topic><topic>Lipids - blood</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Metabolism</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Postmenopause</topic><topic>Tamoxifen - administration & dosage</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Markopoulos, C.</creatorcontrib><creatorcontrib>Chrissochou, M.</creatorcontrib><creatorcontrib>Antonopoulou, Z.</creatorcontrib><creatorcontrib>Xepapadakis, G.</creatorcontrib><creatorcontrib>Papadiamantis, J.</creatorcontrib><creatorcontrib>Tzoracoleftherakis, E.</creatorcontrib><creatorcontrib>Gogas, H.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Markopoulos, C.</au><au>Chrissochou, M.</au><au>Antonopoulou, Z.</au><au>Xepapadakis, G.</au><au>Papadiamantis, J.</au><au>Tzoracoleftherakis, E.</au><au>Gogas, H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Duration of Tamoxifen Effect on Lipidemic Profile of Postmenopausal Breast Cancer Patients following Deprivation of Treatment</atitle><jtitle>Oncology</jtitle><addtitle>Oncology</addtitle><date>2006-01-01</date><risdate>2006</risdate><volume>70</volume><issue>4</issue><spage>301</spage><epage>305</epage><pages>301-305</pages><issn>0030-2414</issn><eissn>1423-0232</eissn><abstract>Objective: It was the aim of this study to investigate the effect of tamoxifen withdrawal on markers of lipid metabolism in postmenopausal women with breast cancer who completed tamoxifen therapy and received no further treatment. Methods: Lipidemic profile changes were studied in 190 postmenopausal patients with operable breast cancer, following cessation of 5–7 years of tamoxifen treatment. Assessments of total cholesterol, high-density lipoprotein, low-density lipoprotein and total serum triglycerides were performed at baseline, 6 months and 12 months. Results: By 6 months, both total cholesterol and low-density lipoprotein levels were significantly increased, and total triglyceride levels were significantly reduced compared with baseline values and maintained to 12 months. There was no significant alteration observed for high-density lipoprotein levels over the study period. Conclusion: The beneficial effect of tamoxifen on the lipidemic profile of postmenopausal breast cancer patients seems to be lost in less than 12 months time following cessation of 5–7 years of tamoxifen treatment. A ‘rebound effect’ on the lipidemic parameters should be expected and those patients should be monitored carefully.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>17047401</pmid><doi>10.1159/000096251</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0030-2414 |
| ispartof | Oncology, 2006-01, Vol.70 (4), p.301-305 |
| issn | 0030-2414 1423-0232 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69027376 |
| source | Karger Journals; MEDLINE |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Agents, Hormonal - administration & dosage Biological and medical sciences Breast cancer Breast Neoplasms - blood Breast Neoplasms - drug therapy Chemotherapy Cholesterol Clinical Study Drug Administration Schedule Female Gynecology. Andrology. Obstetrics Humans Lipid Metabolism - drug effects Lipids Lipids - blood Mammary gland diseases Medical sciences Metabolism Middle Aged Oncology Postmenopause Tamoxifen - administration & dosage Tumors |
| title | Duration of Tamoxifen Effect on Lipidemic Profile of Postmenopausal Breast Cancer Patients following Deprivation of Treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T07%3A11%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Duration%20of%20Tamoxifen%20Effect%20on%20Lipidemic%20Profile%20of%20Postmenopausal%20Breast%20Cancer%20Patients%20following%20Deprivation%20of%20Treatment&rft.jtitle=Oncology&rft.au=Markopoulos,%20C.&rft.date=2006-01-01&rft.volume=70&rft.issue=4&rft.spage=301&rft.epage=305&rft.pages=301-305&rft.issn=0030-2414&rft.eissn=1423-0232&rft_id=info:doi/10.1159/000096251&rft_dat=%3Cproquest_pubme%3E69027376%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220845124&rft_id=info:pmid/17047401&rfr_iscdi=true |